BackEucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Overview

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Total Liabilities

Latest total liabilities for EUCRU: $3.9M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$3.95M
31.90% YoYΔ $-1.85M vs prior year quarter

Peer average

Loading

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Total Liabilities History

Loading

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) vs. peers: Total Liabilities Comparison

Loading

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) (EUCRU) FAQ

The latest total liabilities for EUCRU is $3.9M as of December 2022. That compares with $5.8M in the prior-year period — down 31.9% year over year. Investors often review this figure alongside Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, EUCRU's total liabilities moved from $5.8M to $3.9M — a 31.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s operating scale or balance-sheet position.

A total liabilities figure of $3.9M for EUCRU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EUCRU's total liabilities ($3.9M), review year-over-year change from $5.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.